Generic Name and Formulations:
Palivizumab 50mg/vial, 100mg/vial; liq soln for IM inj; preservative-free.

Company:
MedImmune, Inc.

Indications for SYNAGIS:
Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease (eg, infants with bronchopulmonary dysplasia or born ≤35 wks gestational age), or children with hemodynamically significant congenital heart disease).

Adult:
Not applicable.

Children:
Give by IM injection into anterolateral thigh. 15mg/kg once per month before and during RSV season. Cardiopulmonary bypass: see literature. Divide doses >1mL into 2 inj sites.

Pharmacological Class:
Antiviral monoclonal antibody (IgG1K).

Warnings/Precautions:
Have epinephrine (1:1000) inj available. Thrombocytopenia. Coagulation disorders. May interfere with RSV diagnostic tests (eg, antigen detection-based assays), viral culture assays. Pregnancy (Cat.C).

Adverse Reactions:
Anaphylaxis, hypersensitivity reactions, fever, rash.

How Supplied:
Single-use vials (soln)—1